IL15 and anemia (phenotype): identified in MF patients from two different clinical trials of pomalidomide for MF-associated anemia, that patients with high levels of sIL-2R, IL-8, IL-15, MCP-1, and VEGF at baseline had significantly lower rates of anemia response to treatment (42).